Trial Profile
A Retrospective Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Either of Two One-Year Trials (205.254, 205.255) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record